Form 4: Sangamo Exec's Routine Stock Vesting & Tax Withholding

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, reported routine share dispositions for tax withholding related to restricted stock unit vesting.

Summary

• Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, Inc. (SGMO), reported two dispositions of common stock.
• These dispositions were solely for mandatory tax withholding purposes related to the vesting of Restricted Stock Units (RSUs) under the Issuer's Amended and Restated 2018 Equity Incentive Plan.
• On February 24, 2026, 832 shares were surrendered at a price of $0.4725 per share.
• On February 25, 2026, 5,119 shares were surrendered at a price of $0.47 per share.
• These transactions are explicitly stated as not representing discretionary trades by the reporting person.
• Following these transactions, Gregory D. Davis beneficially owns 185,111 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine, non-discretionary transaction for tax withholding related to executive compensation, with no direct implications for the company's operational or financial performance.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates the fulfillment of compensation agreements for the Head of Research & Technology, reflecting earned equity compensation.

Negatives

• No direct negatives are indicated by these routine tax-related dispositions, as they are non-discretionary administrative events.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports insider transactions for compensation purposes.

Future Outlook

Future vesting installments for Gregory D. Davis's Restricted Stock Unit (RSU) grants are scheduled. Specifically, 49,726 shares from the February 25, 2025 RSU grant will vest as to one-quarter (1/4) on February 25, 2026, with the remainder vesting in 8 successive equal quarterly installments thereafter. Additionally, 37,294 shares from the February 25, 2025 RSU grant will vest in 8 successive equal quarterly installments after the February 25, 2026 installment. All vesting is contingent on continuous service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Management Comments

• The required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as those for tax withholding related to RSU vesting, are common across all industries, particularly in biotechnology companies like Sangamo Therapeutics, where equity compensation is a significant component of executive remuneration. These transactions typically do not reflect a change in management's outlook on the company's prospects but rather an administrative requirement.

Comparison to Industry Standards

• These transactions are standard practice for executive compensation plans involving Restricted Stock Units (RSUs) across publicly traded companies, including peers in the biotechnology sector such as CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT), where executives often surrender shares to cover tax obligations upon vesting.
• The mechanism of surrendering shares to the issuer for tax purposes is a widely adopted method to manage the tax implications of equity awards, aligning with common corporate governance practices for executive incentive plans.

Stakeholder Impact

• Shareholders: Minimal impact, as these are routine tax-related dispositions and not a discretionary sale indicating a change in insider sentiment.
• Employees: The vesting of RSUs is a positive for the executive, representing earned compensation.

Next Steps

• Remaining shares from the February 25, 2025 RSU grant will vest in 8 successive equal quarterly installments after February 25, 2026.
• Vesting of all RSU grants is subject to the Reporting Person's Continuous Service through each date and potential acceleration as provided in the 2018 EIP.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Gregory D. Davis, Biotechnology, Executive Compensation